FY2024 EPS Estimates for Lumos Pharma Boosted by Analyst

Lumos Pharma, Inc. (NASDAQ:LUMO) – Equities research analysts at HC Wainwright upped their FY2024 earnings per share estimates for Lumos Pharma in a research note issued on Thursday, October 24th. HC Wainwright analyst E. White now anticipates that the company will post earnings per share of ($4.12) for the year, up from their previous forecast of ($4.13). HC Wainwright has a “Neutral” rating and a $4.25 price objective on the stock. The consensus estimate for Lumos Pharma’s current full-year earnings is ($2.65) per share. HC Wainwright also issued estimates for Lumos Pharma’s Q4 2024 earnings at ($1.02) EPS and FY2025 earnings at ($2.02) EPS.

A number of other research analysts have also commented on LUMO. Oppenheimer cut their price target on Lumos Pharma from $16.00 to $13.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. EF Hutton Acquisition Co. I raised shares of Lumos Pharma to a “strong-buy” rating in a report on Tuesday, September 24th.

Lumos Pharma Trading Up 1.1 %

Shares of Lumos Pharma stock opened at $4.45 on Monday. The stock has a market capitalization of $36.13 million, a price-to-earnings ratio of -1.00 and a beta of 0.78. Lumos Pharma has a 1-year low of $1.37 and a 1-year high of $4.58. The firm has a fifty day simple moving average of $3.83 and a 200-day simple moving average of $2.85.

Lumos Pharma (NASDAQ:LUMO) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.93) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.33. The business had revenue of $0.49 million for the quarter. Lumos Pharma had a negative return on equity of 157.99% and a negative net margin of 2,405.72%. During the same period in the previous year, the business posted ($1.09) earnings per share.

Institutional Trading of Lumos Pharma

An institutional investor recently raised its position in Lumos Pharma stock. Private Advisor Group LLC lifted its holdings in shares of Lumos Pharma, Inc. (NASDAQ:LUMO) by 2,380.6% in the third quarter, according to its most recent filing with the SEC. The firm owned 744,513 shares of the company’s stock after acquiring an additional 714,500 shares during the period. Private Advisor Group LLC owned approximately 9.17% of Lumos Pharma worth $2,881,000 as of its most recent filing with the SEC. 33.99% of the stock is currently owned by hedge funds and other institutional investors.

Lumos Pharma Company Profile

Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders.